Preclinical rationale for TGF-β inhibition as a therapeutic target for the treatment of myelofibrosis.
about
Efficacy of ALK5 inhibition in myelofibrosis.Upregulation of lysyl oxidase and adhesion to collagen of human megakaryocytes and platelets in primary myelofibrosis.GATA1 insufficiencies in primary myelofibrosis and other hematopoietic disorders: consequences for therapy.Megakaryocyte Contribution to Bone Marrow Fibrosis: many Arrows in the Quiver
P2860
Preclinical rationale for TGF-β inhibition as a therapeutic target for the treatment of myelofibrosis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Preclinical rationale for TGF- ...... he treatment of myelofibrosis.
@en
Preclinical rationale for TGF- ...... he treatment of myelofibrosis.
@nl
type
label
Preclinical rationale for TGF- ...... he treatment of myelofibrosis.
@en
Preclinical rationale for TGF- ...... he treatment of myelofibrosis.
@nl
prefLabel
Preclinical rationale for TGF- ...... he treatment of myelofibrosis.
@en
Preclinical rationale for TGF- ...... he treatment of myelofibrosis.
@nl
P2093
P2860
P50
P1476
Preclinical rationale for TGF- ...... the treatment of myelofibrosis
@en
P2093
Anna Rita Migliaccio
Camelia Iancu-Rubin
Emanuel F Petricoin
Fabrizio Martelli
Francesca Masiello
Ilaria Ceglia
John Mascarenhas
Rona Weinberg
Ronald Hoffman
P2860
P304
1138-1155.e4
P356
10.1016/J.EXPHEM.2016.08.007
P577
2016-08-31T00:00:00Z